Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the Annual B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:25 a.m. EDT in New York, NY. Read more >>